Peak Bio, Inc. (PKBO)

Market Cap	26.48M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	20.06M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130
Open	1.32
Previous Close	1.32
Day's Range	1.32 - 1.32
52-Week Range	1.01 - 15.00
Beta	n/a
Analysts	Buy
Price Target	15.30 (+1,059.09%)
Earnings Date	n/a

About PKBO

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 30
• Stock Exchange: OTCMKTS
• Ticker Symbol: PKBO

Analyst Forecast

According to 7 analysts, the average rating for PKBO stock is "Buy." The 12-month stock price forecast is $15.3, which is an increase of 1,059.09% from the latest price.

Price Target

$15.3

(1,059.09% upside)

Analyst Consensus: Buy